Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- baricitinib
- Envarsus XR (tacrolimus)
Interactions between your drugs
tacrolimus baricitinib
Applies to: Envarsus XR (tacrolimus), baricitinib
GENERALLY AVOID: Coadministration of baricitinib with other immunosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving baricitinib, most of whom were taking concomitant immunosuppressants such as methotrexate or corticosteroids. The most common serious infections reported with baricitinib treatment include pneumonia, herpes zoster, and urinary tract infection. Opportunistic infections include tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus, and BK virus. Lymphoma and other malignancies, including melanoma and non-melanoma skin cancers, have also been observed with the use of baricitinib and other Janus kinase inhibitors.
MANAGEMENT: Concomitant use of baricitinib with other Janus kinase (JAK) inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or potent immunosuppressants (e.g., azathioprine, cyclosporine) is not recommended. Patients receiving baricitinib should be closely monitored for the development of signs and symptoms of infection during and after treatment, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. If a serious infection, an opportunistic infection, or sepsis develops, baricitinib should be interrupted until the infection is controlled.
References (3)
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
- (2018) "Product Information. Olumiant (baricitinib)." Lilly, Eli and Company
Drug and food interactions
tacrolimus food
Applies to: Envarsus XR (tacrolimus)
ADJUST DOSING INTERVAL: Consumption of food has led to a 27% decrease in the bioavailability of orally administered tacrolimus.
MANAGEMENT: Tacrolimus should be administered at least one hour before or two hours after meals.
GENERALLY AVOID: Grapefruit juice has been reported to increase tacrolimus trough concentrations. Data are limited, but inhibition of the CYP450 enzyme system appears to be involved.
MANAGEMENT: The clinician may want to recommend that the patient avoid ingesting large amounts of grapefruit juice while taking tacrolimus.
References (2)
- (2001) "Product Information. Prograf (tacrolimus)." Fujisawa
- Hooks MA (1994) "Tacrolimus, a new immunosuppressant--a review of the literature." Ann Pharmacother, 28, p. 501-11
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Kenalog-40
Kenalog-40 is a long-acting corticosteroid injection for intramuscular (into the muscle) or ...
Olumiant
Olumiant is used to treat rheumatoid arthritis, alopecia areata (hair loss), and COVID-19. Includes ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Zilretta
Zilretta (triamcinolone injection) is used for the management of osteoarthritis pain of the knee ...
Rogaine
Rogaine (minoxidil) is used to help regrow new, thicker hair and prevent future hair loss in men ...
Litfulo
Litfulo is used to treat severe alopecia areata in adults and adolescents 12 years and older to ...
Leqselvi
Leqselvi (deuruxolitinib) is a JAK inhibitor used for the treatment of severe hair loss (alopecia ...
Ritlecitinib
Ritlecitinib is used to improve hair loss in adults and adolescents aged 12 and older with severe ...
Minoxidil topical
Minoxidil topical is a hair loss treatment that helps regrow hair and prevent future hair loss in ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.